Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases that affect both children and adults with a prevalence of 30% and 10%, respectively. Even though most of patients respond satisfactory to topical anti-inflammatory drugs, about 10% require one or more systemic treatments to achieve good control of their illness. The progressive and increasingly detailed knowledge in the immunopathogenesis of AD has allowed research on new therapeutic targets with very promising results in the field of biological therapy. In this article, we will review the different biological treatments with a focus on novel drugs. Their mechanism of action, current status and results from clinical trials and observational studies will be specified.

No abstract

Lymphoblastic lymphomas (LBLs) are uncommon malignant neoplasms derived from immature T‐ or B‐lymphoid progenitor cells. Although cutaneous involvement may reach 33% in B‐LBL, only 12 cutaneous cases of T‐LBL have been published. We report the case of a 49‐year‐old woman with 2‐month history of erythematous‐violaceous plaques in the sternal region and breasts. Histopathologic examination showed a dense monomorphus infiltrate in dermis and positive immunostainings for CD3, CD99 and terminal deoxynucleotidyl transferase, thus indicating T‐LBL. Staging work‐up only revealed a mediastinal mass at diagnosis. After a 51‐month follow‐up and different treatment regimens, the patient remains alive although she has presented four relapses, all of them extramedullary.